期刊文献+

糖皮质激素抵抗机制的研究近况 被引量:8

Research status of glucocorticoid resistance mechanism
下载PDF
导出
摘要 糖皮质激素抵抗是指部分个体对糖皮质激素无反应或反应性明显降低。糖皮质激素抵抗能够使外源性糖皮质激素不能达到预期的治疗效果,内源性糖皮质激素不能完全发挥作用,导致患者疾病不断进展。为了更好地认识糖皮质激素抵抗的原理和机制,使临床能够合理应用糖皮质激素,有效识别和避免糖皮质激素抵抗的发生,本文对近年来的相关研究进行综述。 Glucocorticoid resistanance refers to some individual performance for no response to glucocorticoids or reactivity decreased obviously.Glucocorticoid resistance can not achieve the desired therapeutic effect of exogenous glucoeorticoids,and endogenous glucocorticoids can not fully play a role,then results to the progress of disease.In order to better understand the principle and mechanism of glueocorticoid resistance,reasonable application of glucocorticoid in clinic and effective identification and avoidance of glucocortieoid resistance,this paper reviews the relevant research in recent years.
作者 梁燕
出处 《中国当代医药》 2016年第8期21-23,30,共4页 China Modern Medicine
基金 山东省泰安市科技发展计划项目(201440774-29B)
关键词 糖皮质激素抵抗 糖皮质激素受体 基因多态性 基因突变 Glucocorticoid resistance Glucocorticoid receptor Gene polymorphism Gene mutation
  • 相关文献

参考文献1

二级参考文献181

  • 1Thornberry NA, Bull HG, Calaycay JR, Chapman KT, Howard AD, Kostura MJ, Miller DK, Molineaux SM, Weidner JR, Aun- ins J. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature 1992; 356: 768-774.
  • 2Jin Y, Birlea SA, Fain PR, Spritz RA. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 2007; 127:2558-2562.
  • 3Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC, Fain PR, Spritz RA. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356:1216-1225.
  • 4Magitta NF, Boe Wolff AS, Johansson S, Skinningsrud B, Lie BA, Myhr KM, Undlien DE, Joner G, Njolstad PR, Kvien TK, Forre O, Knappskog PM, Husebye ES. A coding polymor- phism in NALP1 confers risk for autoimmune Addison's dis- ease and type I diabetes. Genes Immun 2009; 10:120-124.
  • 5Tracey KJ,-Cerami A. Tumor necrosis factor: a pleiotropic cy- tokine and therapeutic target. Annu Rev Med 1994; 45:491-503.
  • 6Carroll MC, Katzman P, Alicot EM, KoUer BH, Geraghty DE, Orr HT, Strominger JL, Spies T. Linkage map of the human major histocompatibility complex including the tumor necrosis factor genes. Proc Natl Acad Sci USA 1987; 84:8535-8539.
  • 7Harney SM, Newton JL, Wordsworth BP. Molecular genetics of rheumatoid arthritis. Curr Opin Pharmacol 2003; 3:280-285.
  • 8Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necro- sis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta 2009; 1792:163-172.
  • 9Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associ- ated with HLA A1, B8, and DR3 alleles. J Exp Med 1993; 177: 557-560.
  • 10McManus R, Wilson AG, Mansfield J, Weir DG, Duff GW, Kelleher D. TNF2, a polymorphism of the tumour necrosis-al- pha gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Eur J Immunol 1996; 26: 2113-2118.

共引文献13

同被引文献72

引证文献8

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部